Press release
Hypertension Clinical Trials, Emerging Drugs, Treatment Therapies and Companies 2024
Hypertension Pipeline
Key Takeaways from Hypertension Pipeline Report
• July 2024:- Mineralys Therapeutics Inc.- This study is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications, one of which must be a thiazide or thiazide-like diuretic. A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension.
• July 2024:- Alnylam Pharmaceuticals- A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension. The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
• DelveInsight's Hypertension pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
• The leading companies working in the Hypertension Market include Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.
• Promising Hypertension Pipeline Therapies in the various stages of development include Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.
Request a sample and discover the recent advances in Hypertension Treatment Drugs @ Hypertension Pipeline Report- https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Hypertension pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hypertension Overview
Hypertension is the most common primary diagnosis in the United States. It affects approximately 86 million adults (≥20 years) in the United States and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive medication.
Find out more about Hypertension Therapeutics Assessment @ Hypertension Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Hypertension Emerging Drugs Profile
• Firibastat: Quantum Genomics
• Baxdrostat (CIN-107): CinCor Pharma
• MLS-101: Mineralys Therapeutics
• Zilebesiran (ALN-AGT): Alnylam Therapeutics
• IONIS-AGT-LRx: Ionis Pharmaceuticals
Hypertension Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the Hypertension therapies. The Hypertension companies which have their Hypertension drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.
DelveInsight's Hypertension pipeline report covers around 100+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Hypertension Pipeline Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Learn more about the emerging Hypertension Pipeline Therapies @ Hypertension Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Hypertension Pipeline Report
• Coverage- Global
• Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Hypertension Companies- Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.
• Hypertension Pipeline Therapies- Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.
Dive deep into rich insights for new drugs for Hypertension Treatment, Visit @ Hypertension Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Hypertension: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypertension - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Firibastat: Quantum Genomics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Baxdrostat (CIN-107): CinCor Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ID-140009: IlDong Pharmaceutical
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CKD 331: Chong Kun Dang
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hypertension Key Companies
21. Hypertension Key Products
22. Hypertension- Unmet Needs
23. Hypertension- Market Drivers and Barriers
24. Hypertension- Future Perspectives and Conclusion
25. Hypertension Analyst Views
26. Hypertension Key Companies
27. Appendix
For further information on the Hypertension Pipeline therapeutics, reach out to Hypertension Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Top Selling Market Research Reports in 2024
Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Yash Bhardwaj
info@delveinsight.com
+91-9650213330
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertension Clinical Trials, Emerging Drugs, Treatment Therapies and Companies 2024 here
News-ID: 3650232 • Views: …
More Releases from DelveInsight Business Research LLP
Acute Pain Market to Witness Growth by 2034 | Taiwan Liposome Company, Medical D …
DelveInsight's "Acute Pain Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Acute Pain, historical and forecasted epidemiology as well as the Acute Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Acute Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Acute Pain market size…
Acute Optic Neuritis Market to Rise by 2032 | Bionure, Noveome, Lipocure, and ot …
DelveInsight's "Acute Optic Neuritis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Acute Optic Neuritis, historical and forecasted epidemiology as well as the Acute Optic Neuritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Acute Optic Neuritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted…
Systemic Inflammatory Response Syndrome Market to Rise by 2032 | Cidera Therapeu …
DelveInsight's "Systemic Inflammatory Response Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Systemic Inflammatory Response Syndrome, historical and forecasted epidemiology as well as the Systemic Inflammatory Response Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Systemic Inflammatory Response Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Systemic Juvenile Idiopathic Arthritis Market to Rise by 2032, DelveInsight | No …
DelveInsight's "Systemic Juvenile Idiopathic Arthritis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Systemic Juvenile Idiopathic Arthritis, historical and forecasted epidemiology as well as the Systemic Juvenile Idiopathic Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Systemic Juvenile Idiopathic Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
More Releases for Hypertension
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
4th International Conference on Hypertension & Healthcare
We take the privilege of hosting International Hypertension meetings worldwide and very excited to expand to 4th International Conference on Hypertension & Healthcare to be held in beautiful city Zurich, Switzerland in the month of September 10th- 11th, 2018. As with the three meetings, the Hypertension 2018 will be on high-level updates, debates, hot topics and future research directions in the areas of Cardiology, cardiovascular diseases, Pulmonary Hypertension, Hypertension &…
Ocular Hypertension - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Ocular Hypertension - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H2 2017, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor…
Hypertension: Often unnoticed, always a risk
Vital mushrooms provide a valuable contribution in the prevention and therapy of hypertension
Hypertension is considered one of the greatest health problems of the modern age. In the United Kingdom alone, according to data from the NHS, about 12,5 million people - almost every fourth - are affected. The great danger: Although hypertension can cause further serious diseases, many sufferers do not suspect their hypertension. They feel well and have…
Ocular Hypertension-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Ocular Hypertension-Pipeline Review H2 2017” this report provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include…
Ocular Hypertension - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Ocular Hypertension - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H1 2017, provides an overview of the Ocular Hypertension (Ophthalmology) pipeline landscape.
Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous…
